Reference:	FOI.8192.22	
Subject:	New biologic medications for dermatological conditions	
Date of Request:	10 February 2022	

Requested:

How many patients were treated in January 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibingo)
- Baricitinib (Olumiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

Response:

Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that were treated by the Dermatology Department with the listed medications, for the period 1 to 31 January 2022.

Medication	Number
Abrocitinib (Cibingo)	0
Baricitinib (Olumiant)	38
Bimekizumab (Bimzelx)	0
Brodalumab (Kyntheum)	0
Dupilumab (Dupixent)	21
Ixekizumab (Taltz)	*
Risankizumab (Skyrizi)	0
Guselkumab (Tremfya)	*
Secukinumab (Cosentyx)	23
Tildrakizumab (Ilumetri)	0
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	*
Ustekinumab (Stelara)	50

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act

2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.